II期临床-话题@MedSci

#II期临床#

478篇内容 | 2585人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524827, encodeId=c04d152482eb6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=一款COVID-19的潜在疗法：糖核苷类似物EIDD-2801，已启动II期临床试验, objectType=article, longId=196221, objectId=32501962219e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32501962219e, replyNumber=0, likeNumber=86, createdTime=2020-06-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32501962219e, moduleTitle=一款COVID-19的潜在疗法：糖核苷类似物EIDD-2801，已启动II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32501962219e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524826, encodeId=9a641524826f8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力, objectType=article, longId=196190, objectId=6f67196190f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f67196190f1, replyNumber=0, likeNumber=61, createdTime=2020-06-22, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f67196190f1, moduleTitle=艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f67196190f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524825, encodeId=f0c4152482562, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切, objectType=article, longId=196105, objectId=041919610548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=041919610548, replyNumber=0, likeNumber=60, createdTime=2020-06-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=041919610548, moduleTitle=III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=041919610548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524824, encodeId=07b91524824f4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验, objectType=article, longId=195935, objectId=1c30195935d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c30195935d4, replyNumber=0, likeNumber=13, createdTime=2020-06-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c30195935d4, moduleTitle=关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c30195935d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524823, encodeId=1350152482308, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, objectType=article, longId=195933, objectId=588919593321, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=588919593321, replyNumber=0, likeNumber=0, createdTime=2020-06-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=588919593321, moduleTitle=生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=588919593321)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524822, encodeId=6eff15248226f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=实验性生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, objectType=article, longId=195932, objectId=08a71959323d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08a71959323d, replyNumber=0, likeNumber=14, createdTime=2020-06-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08a71959323d, moduleTitle=实验性生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08a71959323d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524821, encodeId=61de1524821a7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=基因疗法LentiGlobin治疗镰状细胞病：I / II期临床取得积极结果, objectType=article, longId=195867, objectId=ce6c19586e0b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce6c19586e0b, replyNumber=0, likeNumber=65, createdTime=2020-06-15, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce6c19586e0b, moduleTitle=基因疗法LentiGlobin治疗镰状细胞病：I / II期临床取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce6c19586e0b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524820, encodeId=27641524820f4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败, objectType=article, longId=195619, objectId=fa0e195619b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa0e195619b6, replyNumber=0, likeNumber=92, createdTime=2020-06-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa0e195619b6, moduleTitle=默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa0e195619b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524819, encodeId=a5b91524819d8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功, objectType=article, longId=195493, objectId=6fc619549390, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fc619549390, replyNumber=0, likeNumber=94, createdTime=2020-06-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fc619549390, moduleTitle=ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fc619549390)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524818, encodeId=e2821524818aa, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=耐药性晚期癌症如何治疗？靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验, objectType=article, longId=194690, objectId=fbb4194690aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbb4194690aa, replyNumber=0, likeNumber=63, createdTime=2020-05-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbb4194690aa, moduleTitle=耐药性晚期癌症如何治疗？靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbb4194690aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524817, encodeId=3c06152481ea2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究, objectType=article, longId=194645, objectId=1e85194645d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e85194645d2, replyNumber=0, likeNumber=92, createdTime=2020-05-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e85194645d2, moduleTitle=ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e85194645d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524816, encodeId=22ca1524816c4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=靶向Trop-2用于三阴性乳腺癌重磅ADC药物在中国启动II期临床, objectType=article, longId=194629, objectId=5ba51946297d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ba51946297d, replyNumber=0, likeNumber=76, createdTime=2020-05-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ba51946297d, moduleTitle=靶向Trop-2用于三阴性乳腺癌重磅ADC药物在中国启动II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ba51946297d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524815, encodeId=6bb7152481592, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=张伯礼：加快新冠病毒疫苗III期临床试验, objectType=article, longId=194542, objectId=0f3a194542ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f3a194542ed, replyNumber=0, likeNumber=79, createdTime=2020-05-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f3a194542ed, moduleTitle=张伯礼：加快新冠病毒疫苗III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f3a194542ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524814, encodeId=bf2b152481454, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, objectType=article, longId=194316, objectId=c1c619431626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1c619431626, replyNumber=0, likeNumber=63, createdTime=2020-05-19, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1c619431626, moduleTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1c619431626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524813, encodeId=a2cf152481344, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床：赛诺菲的CD38单抗Sarclisa显着降低了多发性骨髓瘤复发患者的死亡风险, objectType=article, longId=194121, objectId=ec9d1941215a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec9d1941215a, replyNumber=0, likeNumber=54, createdTime=2020-05-15, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec9d1941215a, moduleTitle=III期临床：赛诺菲的CD38单抗Sarclisa显着降低了多发性骨髓瘤复发患者的死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec9d1941215a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524812, encodeId=bf4c15248129a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=上周获批II期临床后，Moderna新冠病毒mRNA疫苗又获得FDA授予的快速通道指定, objectType=article, longId=194118, objectId=cc4519411845, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc4519411845, replyNumber=0, likeNumber=72, createdTime=2020-05-15, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc4519411845, moduleTitle=上周获批II期临床后，Moderna新冠病毒mRNA疫苗又获得FDA授予的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc4519411845)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524811, encodeId=ef2415248110f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=学术前沿| 天津总医院杨学军团队发现原研新药ACT001抑制胶质瘤生长新机制 II期临床试验将启动, objectType=article, longId=194057, objectId=3dae19405ec5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dae19405ec5, replyNumber=0, likeNumber=73, createdTime=2020-05-14, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dae19405ec5, moduleTitle=学术前沿| 天津总医院杨学军团队发现原研新药ACT001抑制胶质瘤生长新机制 II期临床试验将启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dae19405ec5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524810, encodeId=6352152481011, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=间充质样细胞产品PLX治疗COVID-19：II期临床即将开展, objectType=article, longId=193909, objectId=e6d31939090f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6d31939090f, replyNumber=0, likeNumber=0, createdTime=2020-05-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6d31939090f, moduleTitle=间充质样细胞产品PLX治疗COVID-19：II期临床即将开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6d31939090f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524809, encodeId=f1261524809d0, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=新型DPEP-1多肽抑制剂Metablok抗击COVID-19：加拿大卫生部批准II期临床, objectType=article, longId=193904, objectId=7e121939040f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e121939040f, replyNumber=0, likeNumber=64, createdTime=2020-05-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e121939040f, moduleTitle=新型DPEP-1多肽抑制剂Metablok抗击COVID-19：加拿大卫生部批准II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e121939040f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524808, encodeId=be45152480872, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, objectType=article, longId=193810, objectId=97c7193810df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97c7193810df, replyNumber=0, likeNumber=59, createdTime=2020-05-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97c7193810df, moduleTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97c7193810df)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

一款COVID-19的潜在疗法：糖核苷类似物EIDD-2801，已启动II期临床试验

2020-06-23

一叶知秋 (审核中...)

前往app查看评论内容

#II期临床#

艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力

2020-06-22

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切

2020-06-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验

2020-06-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展

2020-06-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

实验性生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展

2020-06-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

基因疗法LentiGlobin治疗镰状细胞病：I / II期临床取得积极结果

2020-06-15

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败

2020-06-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功

2020-06-10

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

耐药性晚期癌症如何治疗？靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验

2020-05-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究

2020-05-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

靶向Trop-2用于三阴性乳腺癌重磅ADC药物在中国启动II期临床

2020-05-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

张伯礼：加快新冠病毒疫苗III期临床试验

2020-05-23

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功

2020-05-19

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床：赛诺菲的CD38单抗Sarclisa显着降低了多发性骨髓瘤复发患者的死亡风险

2020-05-15

仁心济世 (审核中...)

前往app查看评论内容

#II期临床#

上周获批II期临床后，Moderna新冠病毒mRNA疫苗又获得FDA授予的快速通道指定

2020-05-15

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

学术前沿| 天津总医院杨学军团队发现原研新药ACT001抑制胶质瘤生长新机制 II期临床试验将启动

2020-05-14

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

间充质样细胞产品PLX治疗COVID-19：II期临床即将开展

2020-05-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

新型DPEP-1多肽抑制剂Metablok抗击COVID-19：加拿大卫生部批准II期临床

2020-05-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力

2020-05-10

科室
- - 订阅+
  - 更多科室
工具
服务